MDGL Projected Dividend Yield
Madrigal Pharmaceuticals Inc ( NASDAQ : MDGL )Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). Co.'s product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-? (THR-?) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). Co.'s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES. 21 YEAR PERFORMANCE RESULTS |
MDGL Dividend History Detail MDGL Dividend News MDGL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |